APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Somatostatin Analogues (LA SSAs)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting Somatostatin Analogues (LA SSAs) Market Outlook and Growth Opportunities 2026

29 December 2025198 pages

Choose your research edition.

Industry ResearchLong-acting Somatostatin Analogues (LA SSAs) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Somatostatin Analogues (LA SSAs) Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Long-acting Somatostatin Analogues (LA SSAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting Somatostatin Analogues (LA SSAs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Somatostatin Analogues (LA SSAs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting Somatostatin Analogues (LA SSAs) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting Somatostatin Analogues (LA SSAs) market include Chiesi Farmaceutici S.p.A, Ipsen, Recordati Rare Diseases, Novartis and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Somatostatin Analogues (LA SSAs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Somatostatin Analogues (LA SSAs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Somatostatin Analogues (LA SSAs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Somatostatin Analogues (LA SSAs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Somatostatin Analogues (LA SSAs) Segment by Company

Chiesi Farmaceutici S.p.A

Ipsen

Recordati Rare Diseases

Novartis

Teva

Long-acting Somatostatin Analogues (LA SSAs) Segment by Type

Injections

Oral Capsules

Long-acting Somatostatin Analogues (LA SSAs) Segment by Application

Neuroendocrine Tumors

Acromegaly

Other

Long-acting Somatostatin Analogues (LA SSAs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting Somatostatin Analogues (LA SSAs) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Long-acting Somatostatin Analogues (LA SSAs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting Somatostatin Analogues (LA SSAs) significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting Somatostatin Analogues (LA SSAs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Somatostatin Analogues (LA SSAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Somatostatin Analogues (LA SSAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Somatostatin Analogues (LA SSAs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Somatostatin Analogues (LA SSAs) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Somatostatin Analogues (LA SSAs) industry.

Chapter 3: Detailed analysis of Long-acting Somatostatin Analogues (LA SSAs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Long-acting Somatostatin Analogues (LA SSAs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Long-acting Somatostatin Analogues (LA SSAs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting Somatostatin Analogues (LA SSAs) Industry Trends Table 2. Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers Table 3. Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges Table 4. Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints Table 5. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Company (2021-2026) Table 7. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Company (2021-2026) Table 9. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Long-acting Somatostatin Analogues (LA SSAs) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Long-acting Somatostatin Analogues (LA SSAs) Key Company Manufacturing Base & Headquarters Table 12. Global Long-acting Somatostatin Analogues (LA SSAs) Company, Product Type & Application Table 13. Global Long-acting Somatostatin Analogues (LA SSAs) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Somatostatin Analogues (LA SSAs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injections Table 18. Significant Companies of Oral Capsules Table 19. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Type (2021-2026) Table 23. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Type (2027-2032) Table 24. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type (2021-2026) Table 28. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Neuroendocrine Tumors Table 30. Significant Companies of Acromegaly Table 31. Significant Companies of Other Table 32. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Application (2021-2026) Table 36. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Application (2027-2032) Table 37. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application (2021-2026) Table 41. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application (2027-2032) Table 42. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026) & (K Units) Table 44. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2021-2026) Table 45. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2027-2032) & (K Units) Table 46. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2027-2032) Table 47. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Region (2021-2026) Table 50. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Region (2027-2032) Table 52. Global Long-acting Somatostatin Analogues (LA SSAs) Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Long-acting Somatostatin Analogues (LA SSAs) Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 57. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2021-2026) Table 58. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 59. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Country (2027-2032) Table 60. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Market Share by Country (2021-2026) Table 62. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Market Share by Country (2027-2032) Table 64. Chiesi Farmaceutici S.p.A Company Information Table 65. Chiesi Farmaceutici S.p.A Business Overview Table 66. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 68. Chiesi Farmaceutici S.p.A Recent Development Table 69. Ipsen Company Information Table 70. Ipsen Business Overview Table 71. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 73. Ipsen Recent Development Table 74. Recordati Rare Diseases Company Information Table 75. Recordati Rare Diseases Business Overview Table 76. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 78. Recordati Rare Diseases Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 83. Novartis Recent Development Table 84. Teva Company Information Table 85. Teva Business Overview Table 86. Teva Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 88. Teva Recent Development Table 89. Key Raw Materials Table 90. Raw Materials Key Suppliers Table 91. Long-acting Somatostatin Analogues (LA SSAs) Distributors List Table 92. Long-acting Somatostatin Analogues (LA SSAs) Customers List Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Long-acting Somatostatin Analogues (LA SSAs) Product Image Figure 2. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (2021-2032) & (K Units) Figure 5. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Long-acting Somatostatin Analogues (LA SSAs) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injections Image Figure 10. Oral Capsules Image Figure 11. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Type (2021-2032) Figure 14. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type (2021-2032) Figure 17. Neuroendocrine Tumors Image Figure 18. Acromegaly Image Figure 19. Other Image Figure 20. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Application (2021-2032) Figure 23. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application (2021-2032) Figure 26. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032) & (US$ Million) Figure 31. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032) & (US$ Million) Figure 37. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Long-acting Somatostatin Analogues (LA SSAs) Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Long-acting Somatostatin Analogues (LA SSAs) Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Injections
  • Oral Capsules
Applications
  • Neuroendocrine Tumors
  • Acromegaly
  • Other
Companies covered
  • Chiesi Farmaceutici S.p.A
  • Ipsen
  • Recordati Rare Diseases
  • Novartis
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032)
  4. 1.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume (2021-2032)
  5. 1.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Long-acting Somatostatin Analogues (LA SSAs) Market Dynamics
  1. 2.1 Long-acting Somatostatin Analogues (LA SSAs) Industry Trends
  2. 2.2 Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers
  3. 2.3 Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges
  4. 2.4 Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints
3 Long-acting Somatostatin Analogues (LA SSAs) Market by Company
  1. 3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Company (2021-2026)
  4. 3.4 Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Company (2021-2026)
  5. 3.5 Global Long-acting Somatostatin Analogues (LA SSAs) Company Ranking (2024-2026)
  6. 3.6 Global Long-acting Somatostatin Analogues (LA SSAs) Company Manufacturing Base and Headquarters
  7. 3.7 Global Long-acting Somatostatin Analogues (LA SSAs) Company Product Type and Application
  8. 3.8 Global Long-acting Somatostatin Analogues (LA SSAs) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Long-acting Somatostatin Analogues (LA SSAs) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Long-acting Somatostatin Analogues (LA SSAs) Market by Type
  1. 4.1 Long-acting Somatostatin Analogues (LA SSAs) Type Introduction
  2. 4.1.1 Injections
  3. 4.1.2 Oral Capsules
  4. 4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Type
  5. 4.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Type
  9. 4.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type (2021-2032)
5 Long-acting Somatostatin Analogues (LA SSAs) Market by Application
  1. 5.1 Long-acting Somatostatin Analogues (LA SSAs) Application Introduction
  2. 5.1.1 Neuroendocrine Tumors
  3. 5.1.2 Acromegaly
  4. 5.1.3 Other
  5. 5.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Application
  6. 5.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Application
  10. 5.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application (2021-2032)
6 Long-acting Somatostatin Analogues (LA SSAs) Regional Sales and Value Analysis
  1. 6.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021-2026
  4. 6.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2027-2032)
  5. 6.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Region (2027-2032)
  9. 6.5 Global Long-acting Somatostatin Analogues (LA SSAs) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032)
  12. 6.6.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032)
  15. 6.7.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032)
  21. 6.9.2 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Country, 2025 VS 2032
7 Long-acting Somatostatin Analogues (LA SSAs) Country-level Sales and Value Analysis
  1. 7.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2032)
  4. 7.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026)
  5. 7.3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032)
  6. 7.4 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Long-acting Somatostatin Analogues (LA SSAs) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Long-acting Somatostatin Analogues (LA SSAs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chiesi Farmaceutici S.p.A
  2. 8.1.1 Chiesi Farmaceutici S.p.A Company Information
  3. 8.1.2 Chiesi Farmaceutici S.p.A Business Overview
  4. 8.1.3 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  6. 8.1.5 Chiesi Farmaceutici S.p.A Recent Developments
  7. 8.2 Ipsen
  8. 8.2.1 Ipsen Company Information
  9. 8.2.2 Ipsen Business Overview
  10. 8.2.3 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  12. 8.2.5 Ipsen Recent Developments
  13. 8.3 Recordati Rare Diseases
  14. 8.3.1 Recordati Rare Diseases Company Information
  15. 8.3.2 Recordati Rare Diseases Business Overview
  16. 8.3.3 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  18. 8.3.5 Recordati Rare Diseases Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Teva
  26. 8.5.1 Teva Company Information
  27. 8.5.2 Teva Business Overview
  28. 8.5.3 Teva Long-acting Somatostatin Analogues (LA SSAs) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  30. 8.5.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Somatostatin Analogues (LA SSAs) Value Chain Analysis
  2. 9.1.1 Long-acting Somatostatin Analogues (LA SSAs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Somatostatin Analogues (LA SSAs) Sales Mode & Process
  6. 9.2 Long-acting Somatostatin Analogues (LA SSAs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Somatostatin Analogues (LA SSAs) Distributors
  9. 9.2.3 Long-acting Somatostatin Analogues (LA SSAs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst